The Effects of Special Patient Population Plasma on Pharmacokinetic Quantifications Using LC-MS/MS
{{output}}
Background: Clinical development of lesinurad, a selective uric acid reabsorption inhibitor, required analysis of lesinurad in plasma from special patient populations. ... ...
